pemivibart (Pemgarda)
Jump to navigation
Jump to search
Indications
- Covid-19 pre-exposure prophylaxis in immunocompromised individuals unlikely to mount a sufficient immune response following vaccination
- persons undergoing active treatment for cancer
- persons receiving CAR T-cell therapy or stem cell transplantation
- persons with hematologic malignancies associated with poor responses to Covid-19 vaccines regardless of treatment status
- solid-organ transplant recipients
- persons with moderate-or-severe primary immunodeficiency
- preson with advanced or untreated HIV1 infection
- persons on high-dose corticosteroids, B-cell depleting agents, & other immunosuppressants
- persons undergoing active treatment for cancer
* emergency use authorization
* likely to be effective for fall 2024 circulating SARS-CoV-2 variants, including KP.3.1.1 & LB.1[2]
Contraindications
- not for use in post-exposure prophylaxis
Dosage
- single intravenous infusion
Mechanism of action
- presumptively, monoclonal antibody to spike glycoprotein of SARS-CoV2
Notes
- CDC still recommends receipt of latest Covid-19 vaccine, wearing a high-quality face mask in public & maintain social distancing
More general terms
References
- ↑ Ingram I New Monoclonal Authorized to Prevent COVID in Immunocompromised People. No such option has been available since FDA revoked the authorization of Evusheld last year. MedPage Today March 22, 2024 https://www.medpagetoday.com/infectiousdisease/covid19/109336
- ↑ 2.0 2.1 Kahn K COVID Preventive Drug Should Work Against Circulating Variants, FDA Now Says. The agency has issued a revised fact sheet for healthcare providers. MedPage Today September 27, 2024 https://www.medpagetoday.com/infectiousdisease/covid19/112152